TY  - JOUR
A1  - Ballo, Olivier
A1  - Eladly, Fagr
A1  - Büttner, Stefan
A1  - Stratmann, Jan Alexander
A1  - Rudolf, Sarah
A1  - Brunnberg, Uta
A1  - Kreisel, Eva-Maria
A1  - Steffen, Björn
A1  - Wagner, Sebastian Alexander
A1  - Finkelmeier, Fabian
A1  - Serve, Hubert
A1  - Brandts, Christian Hubertus
T1  - Acute kidney injury adversely affects the clinical course of acute myeloid leukemia patients undergoing induction chemotherapy
T2  - Annals of hematology
N2  - Acute kidney injury (AKI) complicates the clinical course of hospitalized patients by increasing need for intensive care treatment and mortality. There is only little data about its impact on AML patients undergoing intensive induction chemotherapy. In this study, we analyzed the incidence as well as risk factors for AKI development and its impact on the clinical course of AML patients undergoing induction chemotherapy. We retrospectively analyzed data from 401 AML patients undergoing induction chemotherapy between 2007 and 2019. AKI was defined and stratified according to KIDGO criteria by referring to a defined baseline serum creatinine measured on day 1 of induction chemotherapy. Seventy-two of 401 (18%) AML patients suffered from AKI during induction chemotherapy. AML patients with AKI had more days with fever (7 vs. 5, p = 0.028) and were more often treated on intensive care unit (45.8% vs. 10.6%, p < 0.001). AML patients with AKI had a significantly lower complete remission rate after induction chemotherapy and, with 402 days, a significantly shorter median overall survival (OS) (median OS for AML patients without AKI not reached). In this study, we demonstrate that the KIDGO classification allows mortality risk stratification for AML patients undergoing induction chemotherapy. Relatively mild AKI episodes have impact on the clinical course of these patients and can lead to chronic impairment of kidney function. Therefore, we recommend incorporating risk factors for AKI in decision-making considering nutrition, fluid management, as well as the choice of potentially nephrotoxic medication in order to decrease the incidence of AKI.
KW  - Acute kidney failure
KW  - Acute myeloid leukemia
KW  - Induction chemotherapy
KW  - Survival
KW  - Intensive care treatment
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/81313
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-813130
SN  - 1432-0584
N1  - Open Access funding enabled and organized by Projekt DEAL.
VL  - 100
IS  - 5
SP  - 1159
EP  - 1167
PB  - Springer
CY  - Berlin ; Heidelberg ; New York
ER  -